Celsee Diagnostics has announced the addition of two executives to the growing management team. Mr. Grant Howes has joined the company as Vice President, Commercial Operations, and Mr. Michael Turner as Vice President, Quality Systems and Compliance.
Grant Howes has had a long and successful career focusing on the medical diagnostic and clinical and research cell analyses marketplaces. Prior to joining Celsee Diagnostics, he was Director of Marketing, BD Biosciences, where he was responsible for personal cell analysis systems in the clinical and research markets. Before that, he was Vice President, Marketing, Accuri Cytometers, where he led the commercialization of the company’s innovative flow cytometer.
Michael Turner, another industry veteran, has over twenty years of regulated industry experience. He has played pivotal roles in helping companies build both quality systems and products that meet the standards and requirements of regulatory and accreditation bodies. He most recently served as Director of Operations at Michigan Aerospace Corporation and Springmatter. Prior to that Michael was Director of Quality at BD Biosciences and Senior Director of Quality at Accuri Cytometers.
Kalyan Handique, Chief Executive Officer for Celsee Diagnostics, stated, “Our passion is to make the promise of liquid biopsy a reality. The addition of talented experienced industry experts to our executive management team will help us accelerate sales into the research and CLIA laboratory marketplaces as well as facilitate the process of taking our product through the appropriate regulatory channels for clinical adoption worldwide, including FDA 510K and CE-IVD clearance.”
“I am excited to be part of the Celsee Diagnostics team at this stage in their growth, and to be able to implement a solid long-lasting foundation for the company’s quality system and to facilitate the processes needed for clinical approval of the Celsee products,” said Mr. Turner. “Liquid biopsy has the potential to revolutionize cancer detection, the development of companion diagnostics, as well as the ongoing monitoring of therapeutic outcomes. I look forward to accelerating the growth of the global brand and international sales,” added Mr. Howes.